ÂÜÀòÂÒÂ×

Michal Golan-Mashiach is the Co-Founder & CEO at EdiTy Therapeutics. Prior to this, they were with Applied Genomics, Weizmann Institute of Science, and RADVISION, where they served as team leader. From January 1999 to December 2000, they worked as senior programmer at Amdocs. Michal joined DrGene as Chief Scientific Officer – CSO in April 2012 and served till December 2015.

Michal Golan-Mashiach has played a pivotal role in the full development cycle of all company products, from inception to market. Michal is responsible for defining product strategy, reviewing all relevant literature, performing statistical meta-analyses, identifying available genotyping and sequencing technologies, designing and developing Bioinformatics automated tools, overseeing laboratory processes, quality control and quality assurance procedures, monitoring the analyses, interpreting the results involving physician advisors, creating written reports and communicating findings back to customers. Michal has also been instrumental in building and managing the company's scientific advisory board (SAB) and scientific team.

As part of their role, Michal Golan-Mashiach has accumulated extensive experience with clinical bioinformatics/biostatistics to support data analysis and publication activities – including a variety of genotyping techniques and next-generation sequencing (in particular, methods for Illumina or similar platforms for data analysis).

Michal Golan-Mashiach has a PhD in Systems-Biology from the Weizmann Institute of Science. Michal also has an MBA in Marketing Management from Tel Aviv University, and a M.Sc in Bio-Informatics Systems-Biology from the Weizmann Institute of Science. Michal has a BSc/BA in Computer Science and Economics from Tel Aviv University.

Brian Burke - CBO, Assaf Marcus - VP, Translational Science, and Ofer Levy - VP, R&D report to Michal Golan-Mashiach.